期刊文献+

高强度聚焦超声热疗治疗31例胰腺癌的临床分析 被引量:4

High intensity focused ultrasound in patients with pancreatic carcinoma
下载PDF
导出
摘要 目的探讨高强聚焦超声(HIFU)热疗对胰腺癌患者的疗效、安全性及对几种肿瘤标志物的影响。方法31例胰腺癌患者平均每例患者行7.2次HIFU治疗,对其进行疗效评价,观察患者的临床受益反应(CBR)、肿瘤客观评价、化学免疫分析法检测CA19-9、CA242和CEA浓度。结果31例胰腺癌患者中共20例临床受益,CBR率达64.51%。治疗前-后CA19-9、CA242、CEA浓度差异具有统计学意义。在治疗过程中无明显副作用。结论高强聚焦超声热疗能控制肿瘤进展、改善生活质量、对肿瘤标志CA19-9、CA242、CEA有有明显下调作用,无明显不良反应。 Objective To investigate the therapeutic effect, safety and the effect of several tumor markers of high intensity focused ultrasound (HIFU) in treating pancreatic carcinoma. Methods The 31 patients suffering from pancreatic carcinoma received 7.2 times in average HIFU treatment, and we observed therapeutic effects including of clinical benefit response, tumorous objective evaluation, the concentration of several tumor markers to utilize chemo-immunity analytical method detecting of carbohydrate antigen 19-9 (CA19-9), CA 242, carcino-embryonic antigen(CEA). Re- sults There were 20 clinical benefit response among 31 pancreatic carcinoma patients received high intensity focused ultrasound (HIFU). The clinical benefit response rate was 64.51%. The concentration of CA19-9, CA242, CEA, the variability was significant before and after the treatment. The treatment course was well in the observation group. The complicated symptoms did not perform after the treatment. Conclusion The HIFU in treating pancreatic carcinoma can control the progress of tumor, improve the quality of life, and prolong overall survival. It also can reduce CA19-9, CA242 and CEA levels. Furthermore, no significant adverse reaction oecurres in the treatment.
出处 《胃肠病学和肝病学杂志》 CAS 2008年第9期711-713,共3页 Chinese Journal of Gastroenterology and Hepatology
关键词 高强度聚焦超声 胰腺癌 High intensity focused ultrasound Pancreatic carcinoma
  • 相关文献

参考文献9

  • 1McKenna S, Eatoek M. The medical management of pancreatic cancer: a review[J]. Oncologist, 2003, 8(2) :149-160.
  • 2Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment[J]. Cancer, 1981, 47(1): 207-14.
  • 3Haller DG. New perspectives in the management of pancreas cancer [J]. Semin Oncol, 2003, 30(4 Suppl 11): 3-10.
  • 4Wu F, Chen WZ, Bai J, et al. Tumor vessel destruction resuhing form high inlensity focused uhrasound in patients with solid malignancies [J]. Ultrasound Med Biol, 2002, 28(4): 535-542.
  • 5McKenna S, Eatock M. The medical management of pancreatic cancer [J]. Oncologist, 2003, 8(2): 149-160.
  • 6Wang X, Sun J, High-intensity focused uhrasound in patients with late-stage pancreatic carcinoma[ J]. Chin Med J (Engl) , 2002, 115 (9) : 1332-1335.
  • 7Okada S. Evaluation of antitumor effect of chemotherapy for pancreatic cancer[J]. Gan To Kagaku Ryoho, 1997, 24(14) :2031-2035.
  • 8Halm U, Schumann T, Schiefke I, et al. Decrease of CA19-9 during chemotherapy with gemcitahine predicts survival time in patients with advanced pancreatic cancer [ J ]. Br J Cancer, 2000, 82 ( 5 ) : 1013-1016.
  • 9Ni XG, Bai XF, Mao YL, et al. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer[J]. Eur J Surg Oncol, 2005, 31 (2) :164-169.

同被引文献50

引证文献4

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部